Search Results
Jul 02, 2026, 10:53 ET Ribo und Madrigal erreichen ersten wichtigen Meilenstein bei der Weiterentwicklung neuartiger siRNA-Therapien für MASH
Tochtergesellschaft Ribocure Pharmaceuticals AB (zusammen als „Ribo" bezeichnet) geben in Zusammenarbeit mit Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) bekannt, dass im Rahmen ihrer siRNA-Partnerschaft der Meilenstein der Nominierung des ersten Wirkstoffkandidaten erfolgreich erreicht wurde. Dieser
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 02, 2026, 02:27 ET Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH
Ltd. (06938.HK) y su filial Ribocure Pharmaceuticals AB (en adelante, "Ribo"), en colaboración con Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL), han dado a conocer el logro del primer hito de nominación de fármaco candidato dentro de su alianza en el campo del siRNA. Este hito es el resultado
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 02, 2026, 00:43 ET Ribo et Madrigal franchissent une première étape majeure dans le développement de nouvelles thérapies à base d'ARNsi pour la stéatohépatite associée à un dysfonctionnement métabolique (MASH)
Ribocure Pharmaceuticals AB (désignées collectivement sous le nom de « Ribo »), en collaboration avec Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ : MDGL), annoncent avoir franchi avec succès la première étape clé de la désignation d'un candidat-médicament dans le cadre de leur partenariat sur les ARNsi.
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 01, 2026, 21:39 ET Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 01, 2026, 21:19 ET Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 31, 2026, 20:49 ET The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
haunted earlier CRISPR approaches. The technology promises more precise manufacturing of gene-corrected cells at scale. Madrigal Pharmaceuticals (NASDAQ: MDGL) presented two-year data showing its therapy Rezdiffra significantly improved liver stiffness and fibrosis biomarkers in patients with compensated MASH
More news about: USA News Group
Mar 24, 2026, 10:00 ET Advanced Cell-based Therapy Booming the Success for Healthcare Sector
path from edited cell to approved therapy is measured in years of development, trials, and manufacturing scale-up. Madrigal Pharmaceuticals (NASDAQ: MDGL) presented two-year data showing its therapy, Rezdiffra, significantly improved liver stiffness and fibrosis biomarkers in patients with compensated
More news about: USA News Group
Feb 12, 2026, 05:47 ET Ribo und Ribocure geben exklusive globale Lizenzvereinbarung mit Madrigal für neuartige siRNA-Therapeutika gegen MASH bekannt
Pharmaceuticals AB („Ribocure") gaben heute bekannt, dass sie eine exklusive weltweite Lizenzvereinbarung mit Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) („Madrigal") eine exklusive weltweite Lizenzvereinbarung für sechs präklinische Small-Interfering-RNA (siRNA)-Programme zur Behandlung von metabolischer
More news about: Suzhou Ribo Life Science Co., Ltd.
Feb 12, 2026, 05:44 ET Ribo et Ribocure annoncent un accord de licence mondial exclusif avec Madrigal pour de nouvelles thérapies pARNi ciblant la stéatohépatite associée à un dysfonctionnement métabolique (MASH)
Pharmaceuticals AB (« Ribocure ») ont annoncé aujourd'hui avoir conclu un accord de licence mondial exclusif avec Madrigal Pharmaceuticals, Inc. (NASDAQ : MDGL) (« Madrigal ») pour six programmes précliniques de petits ARN interférents (pARNi) pour le traitement de la stéatohépatite associée à un dysfonctionnement
More news about: Suzhou Ribo Life Science Co., Ltd.
Feb 11, 2026, 13:49 ET Ribo y Ribocure anuncian un acuerdo de licencia global exclusivo con Madrigal
Pharmaceuticals AB ("Ribocure") anunciaron hoy que han firmado un acuerdo de licencia mundial exclusivo con Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) ("Madrigal") para seis programas preclínicos de ARN de interferencia pequeño (siRNA) para el tratamiento de la esteatohepatitis asociada a disfunción
More news about: Suzhou Ribo Life Science Co., Ltd.
Feb 11, 2026, 06:49 ET Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
More news about: Suzhou Ribo Life Science Co., Ltd.
Feb 11, 2026, 06:25 ET Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
More news about: Suzhou Ribo Life Science Co., Ltd.
Jan 02, 2026, 13:29 ET Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
(NASDAQ: VRTX), CRISPR Therapeutics (NASDAQ: CRSP), Prime Medicine, Inc. (NASDAQ: PRME), and Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
More news about: Equity Insider